Transactions
3
Insider / Guardant Health, Inc.
Azar Alex M II
Director at Guardant Health, Inc.
- Company
- Guardant Health, Inc.
- Ticker
- GH
- First filing on record
- October 13, 2026
- Latest trade on record
- October 14, 2026
- SEC filings
- EDGAR ↗
Azar Alex M II, Director at Guardant Health, Inc., has disclosed 3 transactions in GH since October 13, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $11K at the reported prices. The latest was filed October 15, 2026, 1 day after the trade.
Open-market buys
0
Sales
1
Avg. disclosure lag
1.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Azar Alex M II made no purchases and 1 sale worth $11K, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Azar Alex M II has traded 1 stock on record; the largest by dollars is GH.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 2 | 274 | — |
| S | Open-market sale | 1 | 69 | $11K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 1 · $11K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| GH | Sell S | October 14, 2026 | October 15, 2026 | 1d | 69 | $160 | $11K | 10b5-1 plan | Form 4 ↗ | |
| GH | Option / conversion M | October 12, 2026 | October 13, 2026 | 1d | 137 | — | — | derivative | Form 4 ↗ | |
| GH | Option / conversion M | October 12, 2026 | October 13, 2026 | 1d | 137 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 15, 2026 | Form 4 | 0001402256-26-000010 | 1 | published | EDGAR ↗ |
| October 13, 2026 | Form 4 | 0001402256-26-000008 | 2 | published | EDGAR ↗ |
Other insiders at Guardant Health, Inc.
- Chudova Darya Chief Technology Officer 9 rows
- Freeman Chris Chief Commercial Officer 9 rows
- Kalia Kumud Chief Information Officer 9 rows
- Saia John G. Chief Legal Officer 9 rows
- Eltoukhy Helmy Co-Chief Executive Officer 8 rows
- Talasaz AmirAli Co-Chief Executive Officer 8 rows
- Bell Michael Brian Chief Financial Officer 7 rows
- Hidalgo Medina Manuel Director 5 rows
- Monroe Terilyn J. Chief People Officer 5 rows
- MIGNONE ROBERTO Director 3 rows
Everyone on file, with contracts and lobbying under the company's name: Guardant Health, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 3 | October 13, 2026 | October 15, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.